A Phase 3, Randomized, Double-Blind, Placebo- and Active- Comparator-Controlled Clinical study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With High-Risk Stage II-IV Melanoma

  • Haydon, Andrew (Primary Chief Investigator (PCI))
  • Brooks, Christine (Project Manager)

Project: Research

Project Details

StatusFinished
Effective start/end date2/08/23 → 1/08/25

Keywords

  • Clinical trial
  • V940-001

Clinical Trial Phase

  • Phase III (a & b)